EUVIMEDEUVIMED entdecken
Crossref

Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma

Heesook Oh, Jisook Kim, Seung Hyun Jung, Tae Hee Ha, Young Gil Ahn, Gibeom Nam, Kyeongwon Moon, Pargat Singh iD, In Su Kim iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00758 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Heesook Oh und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 4, Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is responsible for 90% of cases. Approximately 30% of patients diagnosed with HCC are identified as displaying an aberrant expression of fibroblast growth factor 19 (FGF19)-fibroblast growth factor receptor 4 (FGFR4) as an oncogenic-driver pathway. Therefore, the control of the FGF19-FGFR4 signaling pathway with selective FGFR4 inhibitors can be a promising therapy for the treatment of HCC. We herein disclose the design and synthesis of novel FGFR4 inhibitors containing a 2,6-naphthyridine scaffold. Compound 11 displayed a nanomolar potency against Huh7 cell lines and high selectivity over FGFR1-3 that were comparable to that of fisogatinib (8) as a reference standard. Additionally, compound 11 demonstrated remarkable antitumor efficacy in the Huh7 and Hep3B HCC xenograft mouse model. Moreover, bioluminescence imaging experiments with the orthotopic mouse model support that compound 11 can be considered a promising candidate for treating HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Fibroblast Growth Factor, Type 4Carcinoma, HepatocellularLiver NeoplasmsAntineoplastic AgentsNaphthyridinesHumansAnimalsMiceCell Line, TumorStructure-Activity RelationshipXenograft Model Antitumor AssaysProtein Kinase InhibitorsCell ProliferationDrug DiscoveryMice, NudeDrug Screening Assays, Antitumor

Substanzen

Receptor, Fibroblast Growth Factor, Type 4Antineoplastic AgentsFGFR4 protein, humanNaphthyridinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
  • Hanmi Research Center, Hanmi Pharmaceutical Co., Ltd., Hwaseong 18469, Republic of Korea.

ORCID-Profile: Pargat Singh, In Su Kim

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Oh, H., Kim, J., Jung, S. H., Ha, T. H., Ahn, Y. G., Nam, G., Moon, K., Singh, P., & Kim, I. S. (2024). Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00758

Vancouver

Oh H, Kim J, Jung SH, Ha TH, Ahn YG, Nam G, et al. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00758

BibTeX
@article{Oh2024,
  author = {Oh, Heesook and Kim, Jisook and Jung, Seung Hyun and Ha, Tae Hee and Ahn, Young Gil and Nam, Gibeom and Moon, Kyeongwon and Singh, Pargat and Kim, In Su},
  title = {Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00758}
}
Kostenlos starten →